Page 5 - Daptorum Group News Today

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology

The prevalence of obesity has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Obesity and the growing research and

/PRNewswire/ -- DelveInsights Obesity Pipeline Insight – 2022 report provides comprehensive global coverage of available, marketed, and pipeline obesity...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology

ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(Euronext Paris:APM), a clinical stage biopharmaceutical company dedicated to

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases,

NEW YORK, NY and LONDON, UK, and PARIS, FRANCE / ACCESSWIRE / August 19, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) a clinical stage biopharmaceutical

Press release content from Accesswire. The AP news staff was not involved in its creation.